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Introduction {#sec1}
============

Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer, comprising 8%--14% of all breast cancer cases ([@bib17], [@bib27]). ILC is histologically characterized by single-cell files of tumor cells in a fibrous stroma. Due to its invasive growth behavior, this tumor type does not immediately form a defined tumor mass and, therefore, is difficult to detect by physical examination or mammography ([@bib14]). Despite being classified as a histologic low-grade tumor type with a low-to-intermediate mitotic index, the infiltrating nature of ILC complicates surgical removal. Moreover, ILCs typically respond poorly to classical regimes of chemotherapy. To improve treatment options, more insight into ILC development is required.

On the molecular level, ILC is characterized by loss of the cell-adhesion protein E-cadherin ([@bib23]), an event that has been shown to drive tumor invasion. Nevertheless, somatic inactivation of E-cadherin in mouse mammary epithelium does not induce spontaneous mammary tumor development ([@bib3], [@bib8]), indicating that additional (epi)genetic lesions are required for ILC formation. Activation of the phosphatidylinositol 3-kinase (PI3K) pathway, as displayed by either activating *PIK3CA* mutations or homozygous deletions or inactivating mutations in *PTEN*, is frequently observed in ILC ([@bib4], [@bib6], [@bib21], [@bib22]). PI3K signaling controls multiple cellular processes, such as cell proliferation, survival, and migration, by the conversion of phosphatidylinositol 4,5-bisphosphate (PIP~2~) to phosphatidylinositol (3,4,5)-trisphosphate (PIP~3~), driving activation of downstream targets such as AKT. To test whether constitutive activation of PI3K signaling can, indeed, drive the formation of ILC, we generated mice with mammary-specific Cre-conditional inactivation of E-cadherin and PTEN. We found that combined loss of both E-cadherin and PTEN in mouse mammary epithelial cells induces mouse mammary tumors that closely resemble classical invasive lobular carcinoma (CLC), the main subtype of human ILC.

Results {#sec2}
=======

Inactivation of E-Cadherin and PTEN In Vitro Alters Growth and Invasion of Mammary Epithelium {#sec2.1}
---------------------------------------------------------------------------------------------

To study the direct consequence of inactivation of E-cadherin (encoded by the *Cdh1* gene) and PTEN in primary mammary epithelial cells, we generated mammary organoids from *Cdh1*^*F/F*^*;Pten*^*F/F*^ mice ([@bib8], [@bib20]). In vitro transduction of organoids using a Cre-recombinase-encoding adenovirus (AdCre) allowed us to test the direct effects of E-cadherin and PTEN loss in mammary epithelium. To confirm efficient AdCre-mediated recombination in vitro, we used organoids from *mTmG* reporter mice that express tandem dimer Tomato (tdT) prior to recombination and GFP after Cre-mediated excision of tdT ([@bib24]). AdCre transduction of *mTmG* organoids induced loss of tdT and expression of GFP in nearly all cells ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Importantly, the phenotype of AdCre-transduced *mTmG* organoids appeared unaltered as compared to non-transduced organoids from the same mouse, indicating that organoid growth rate and phenotype are not affected by AdCre transduction ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This strategy was, therefore, applied to inactivate E-cadherin and/or PTEN in *Cdh1*^*F/F*^, *Pten*^*F/F*^, and *Cdh1*^*F/F*^*;Pten*^*F/F*^ organoids, respectively. All non-transduced organoids displayed similar-sized cyst-like structures after 7 days of culture ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The inactivation of E-cadherin altered mammary organoid phenotype by inducing discohesive cellular structures surrounding the organoid cores, while the inactivation of PTEN resulted in enlarged smooth-edged organoids ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Concurrent inactivation of E-cadherin and PTEN revealed a combined phenotype of *Cdh1*^*Δ/Δ*^ and *Pten*^*Δ/Δ*^ organoids, as *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ organoids were both enlarged and showed discohesive cellular structures ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Efficient recombination was confirmed by western blotting and PCR, showing strong reduction of E-cadherin and/or PTEN protein expression and deletion of the *Cdh1*^*F*^ and *Pten*^*F*^ alleles, respectively ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}C). In addition, AdCre-transduced *Pten*^*F/F*^ and *Cdh1*^*F/F*^*;Pten*^*F/F*^ organoids showed a strong induction of AKT phosphorylation, indicating activation of PI3K signaling due to PTEN loss ([Figure 1](#fig1){ref-type="fig"}A).

To study the long-term consequences of E-cadherin and/or PTEN loss in mammary epithelial cells, we monitored organoid development over a period of 21 days. Non-transduced organoids from each genotype decreased similarly in size and were hardly detectable after 21 days of culture ([Figure 1](#fig1){ref-type="fig"}B). The size of *Cdh1*^*Δ/Δ*^ organoids remained stable, while the size of *Pten*^*Δ/Δ*^ and *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ organoids continued to increase ([Figures 1](#fig1){ref-type="fig"}B and 1C). Again, the margins of both *Cdh1*^*Δ/Δ*^ and *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ organoids showed discohesive cellular structures ([Figure 1](#fig1){ref-type="fig"}B).

To examine why growth kinetics differed between *Cdh1*^*Δ/Δ*^ and *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ organoids, we analyzed cell proliferation and apoptosis by immunofluorescence (IF) with antibodies against Ki-67 and cleaved caspase-3 (CC3), respectively. *Cdh1*^*Δ/Δ*^ organoids showed a balanced number of cells in proliferation or apoptosis, which might explain their sustained size over time ([Figures 1](#fig1){ref-type="fig"}D and 1E). Consistent with a survival role for the PI3K signaling pathway, both *Pten*^*Δ/Δ*^ and *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ organoids showed almost no apoptotic cells ([Figure 1](#fig1){ref-type="fig"}E), resulting in an increase in organoid size over time ([Figures 1](#fig1){ref-type="fig"}B and 1C).

In contrast to *Pten*^*Δ/Δ*^ organoids, *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ organoids displayed an invasive response upon renewal of the cell culture medium ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}D). These invasive cellular strands displayed single files of cells, indicating an increased invasive potential of *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ mammary epithelium upon stimulation by growth factors and/or chemoattractants in the culture medium.

Together, these observations suggest that PI3K pathway activation through the disruption of PTEN can rescue apoptosis induced by E-cadherin loss in mammary epithelial organoids, resulting in invasive and proliferative behavior in vitro.

Inactivation of E-Cadherin and PTEN in Mammary Epithelium In Vivo Induces Rapid Formation of Hyperplastic and Infiltrative Lesions {#sec2.2}
----------------------------------------------------------------------------------------------------------------------------------

To study the consequences of E-cadherin and PTEN loss in vivo, we generated *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ female mice, in which mammary-epithelium-specific inactivation of E-cadherin and PTEN is induced by whey acidic protein (*WAP*) gene promoter-driven Cre recombinase (*Wcre*) ([@bib8]). We also generated *Wcre;Cdh1*^*F/F*^ and *Wcre;Pten*^*F/F*^ female mice to study the effects of E-cadherin or PTEN loss alone. Since *Wcre* activity is first detectable in the fourth week of mammary gland development (data not shown), we analyzed the consequences of somatic inactivation of E-cadherin and/or PTEN during mammary gland development. Histological analysis and immunohistochemistry (IHC) for cytokeratin 8 (CK8; marking luminal mammary epithelial cells) indicated inactivation of E-cadherin to cause hyperplastic and dysplastic ducts, as well as a marked accumulation of dissociated mammary epithelial cells in the lumen of mammary epithelium from 6-week-old *Wcre;Cdh1*^*F/F*^ mice ([Figure 2](#fig2){ref-type="fig"}A). Inactivation of PTEN alone did not reveal distinct alterations in mammary epithelial composition in *Wcre;Pten*^*F/F*^ ([Figure 2](#fig2){ref-type="fig"}A). In contrast, mammary epithelium from 6-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice displayed multifocal neoplastic lesions infiltrating the surrounding stroma ([Figure 2](#fig2){ref-type="fig"}A). Analysis of over 20 nulliparous *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice confirmed a robust synergy between loss of E-cadherin and PTEN in driving formation of these mammary epithelial lesions, as all mice displayed neoplastic lesions at 6 weeks of age. The infiltration pattern of these neoplastic lesions showed strong resemblance with the characteristic trabecular and discohesive growth pattern of tumor cells in human CLC. We confirmed *Wcre*-mediated inactivation of E-cadherin and/or PTEN in luminal epithelial cells by IF ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). Analysis of *Wcre;Cdh1*^*F/F*^ glands showed that E-cadherin-deficient cells in the lumen are CK8 positive, indicating that these cells indeed dissociated from the luminal epithelium ([Figure S2](#mmc1){ref-type="supplementary-material"}A). This phenomenon is likely caused by reduced junctional integrity following E-cadherin loss ([@bib30]). Even though *Wcre;Pten*^*F/F*^ glands did not display neoplastic lesions within 6 weeks, we clearly observed stochastic loss of PTEN in luminal epithelial cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The neoplastic lesions observed in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mammary glands displayed discohesive CK8-marked luminal epithelial cells that, indeed, lost E-cadherin and PTEN, whereas surrounding stromal cells retained PTEN expression ([Figure 2](#fig2){ref-type="fig"}B). Moreover, E-cadherin-deficient cells still expressed CK8, indicating that these cells did not undergo epithelial-to-mesenchymal transition (EMT), as also previously observed ([@bib8]).

Since inactivation of PTEN rescued apoptosis and promoted survival of E-cadherin-deficient mammary epithelial cells in *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ organoids, we analyzed apoptosis by CC3 IF staining in mammary gland sections from 6-week-old *Wcre;Cdh1*^*F/F*^, *Wcre;Pten*^*F/F*^, and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. While no apoptosis was observed in *Wcre;Pten*^*F/F*^ and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mammary glands, CK8-positive cells in the lumen of mammary ducts in *Wcre;Cdh1*^*F/F*^ mice displayed CC3-marked apoptosis ([Figures 2](#fig2){ref-type="fig"}C and 2D). Compared to *Cdh1*^*Δ/Δ*^ organoids, *Wcre;Cdh1*^*F/F*^ mammary glands showed only limited numbers of CC3-marked cells, most likely due to rapid clearance of apoptotic cells in the lumen of mammary ducts. These data underscore the notion that the loss of PTEN promotes survival of E-cadherin-deficient mammary epithelial cells through inhibition of apoptosis.

To further investigate the effects of concomitant inactivation of E-cadherin and PTEN on mammary gland development and functionality, we analyzed mammary gland outgrowth during puberty and mammary gland maturation during pregnancy in nine *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. Whole-mount analysis of mammary glands from 8-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice showed, beside neoplastic lesions and hyperplastic ducts, a delay in mammary gland development, as compared to age-matched wild-type mammary glands ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Impaired mammary gland maturation was also observed during pregnancy, as pups from five 12-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice grew poorly and died 6 days after birth, while littermates fostered onto wild-type dams showed normal weight and survival ([Figure S2](#mmc1){ref-type="supplementary-material"}C). This phenomenon is likely caused by the reduced numbers of milk-producing glands in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, as compared to wild-type foster dams ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Thus, both the development and maturation of *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ mammary epithelium is strongly impaired, which is likely caused by the loss of mammary epithelial integrity and formation of multi-focal neoplasia.

Inactivation of E-Cadherin and PTEN Drives Formation of Mammary Tumors that Closely Resemble Human CLC {#sec2.3}
------------------------------------------------------------------------------------------------------

To examine potential synergy between E-cadherin and PTEN loss in mammary tumorigenesis, we monitored tumor formation, as detected by palpation, in *Wcre;Pten*^*F/+*^, *Wcre;Pten*^*F/F*^, *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^, and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. In line with previous literature, female *Wcre;Pten*^*F/+*^ and *Wcre;Pten*^*F/F*^ mice developed heterozygous or homozygous mammary tumors, with median latencies of 615 and 250 days, respectively ([Figure 3](#fig3){ref-type="fig"}A) ([@bib16]). Additional inactivation of E-cadherin significantly decreased mammary tumor latency to 109 days of age in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, demonstrating strong synergy between E-cadherin and PTEN loss in mammary tumorigenesis ([Figure 3](#fig3){ref-type="fig"}A). Interestingly, *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ and *Wcre;Pten*^*F/+*^ female mice showed a similar tumor-free survival, indicating that complete loss of PTEN is required for malignant transformation of E-cadherin-deficient mammary epithelial cells ([Figure 3](#fig3){ref-type="fig"}A).

To analyze the mammary tumors for each genotype, mice were sacrificed when tumors reached 225 mm^2^, except for *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, which were sacrificed after a median period of 101 days after tumor detection due to cumulative burden of multifocal tumors, abnormal locomotory behavior, or skin ulceration (both associated with infiltrating tumor cells in surrounding tissues) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Mammary tumors from *Wcre; Pten*^*F/+*^mice displayed diverse histological phenotypes, including solid carcinomas, squamous metaplastic carcinomas, and EMT-like tumors, while *Wcre; Pten*^*F/F*^ mice solely developed squamous metaplastic carcinomas ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A), suggesting that somatic PTEN loss, on its own, preferentially drives the development of this particular tumor type.

Notably, additional inactivation of E-cadherin completely shifted mammary tumor morphology. About half (57%) of mammary tumors in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ mice and nearly all (96%) tumors in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice displayed infiltrative patterns of single files of tumor cells into the surrounding stroma ([Figures 3](#fig3){ref-type="fig"}B and 3C). IHC staining of tumor sections confirmed the absence of E-cadherin and PTEN protein in CK8-marked tumor cells, whereas surrounding stromal cells retained PTEN expression ([Figure 3](#fig3){ref-type="fig"}C). Moreover, IHC staining revealed elevated levels of phosphorylated (p)-AKT, p-4ebp1, and p-S6 in tumor cells, confirming the activation of PI3K signaling due to loss of PTEN ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Given that this phenotype comprises key characteristics of human CLC, we designated these tumors as mouse CLC (mCLC). Interestingly, mCLCs from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ mice completely lost PTEN protein expression as analyzed by IHC, indicating that ILC formation requires complete loss of PTEN expression ([Figure S3](#mmc1){ref-type="supplementary-material"}E). The remaining mammary tumors from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ mice were classified as solid ILC, squamous metaplastic carcinomas, or EMT-like tumors that possibly developed due to incomplete loss of PTEN expression ([Figure 3](#fig3){ref-type="fig"}B).

Since the majority of human CLCs are estrogen receptor (ER) positive, we analyzed ER expression in mCLCs from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, revealing a mean of 26% ER-positive tumor cells ([Figures 3](#fig3){ref-type="fig"}C, 3D, and [S3](#mmc1){ref-type="supplementary-material"}C). In contrast, a mean of only 0.1% ER-positive cells was observed in *Brca1*^*Δ/Δ*^*;Trp53*^*Δ/Δ*^ mouse mammary tumors, which are known to be ER negative ([@bib18]). Also, the expression of *Esr1* mRNA, encoding ERα, was found to be increased in *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ mCLCs, as compared to *Brca1*^*Δ/Δ*^*;Trp53*^*Δ/Δ*^ mouse mammary tumors ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Expression of *Esr1* mRNA was also observed in FACS (fluorescence-activated cell sorting)-sorted EpCAM (epithelial cell adhesion molecule)-positive tumor cells, confirming the ER positivity of tumor cells in mCLC ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3F).

Based on their gene expression profiles, human CLCs are classified as luminal-A tumors ([@bib6], [@bib15]). To assess the molecular subtype of mCLCs from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, hierarchical clustering of RNA-seq data from 956 human breast cancers and 42 mouse mammary tumors was performed using the PAM50 gene set, which allows classification of breast tumors into luminal, basal-like, HER2-positive and normal-like subgroups ([@bib26]). Whereas the 22 *Brca1*^*Δ/Δ*^*;Trp53*^*Δ/Δ*^ mammary tumors clustered together with human basal-like breast cancers, all 20 *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ mCLCs were classified as luminal-A tumors, indicating that these mouse tumors closely resemble the molecular subtype of human CLC ([Figure 3](#fig3){ref-type="fig"}E). In summary, the combined loss of E-cadherin and PTEN drives a rapid onset of mCLCs that recapitulate the morphology, ER positivity, and molecular subtype of human CLC.

Mammary Gland Reconstitution Exposes Slow and Linear Growth of De Novo mCLCs {#sec2.4}
----------------------------------------------------------------------------

Human CLCs are typically slow-growing tumors with a low-to-intermediate mitotic index. Unfortunately, mCLC growth kinetics could not be measured in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, which display multifocal tumor formation in all mammary glands. To assess the growth kinetics of mCLCs, we performed mammary gland reconstitutions by orthotopic transplantation of small fragments of tumor-free mammary gland tissue from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice into cleared mammary fat pads of wild-type mice. In 82 out of 104 reconstituted mammary glands, a palpable tumor was detected after a median latency period of 102 days, which is similar to the median latency of 109 days in the spontaneous mouse model ([Figure 4](#fig4){ref-type="fig"}A). Since tumor development after mammary gland reconstitution occurred at a single location, it allowed reliable assessment of tumor size. Up to 250 days after tumor detection, which is more than twice the age the spontaneous mouse model reaches, a linear and slow growth rate was observed for all 82 tumors to an average size of only 8.6 mm^2^ ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S4](#mmc1){ref-type="supplementary-material"}A). These linear growth kinetics are unique for mouse tumors, which generally exhibit exponential tumor growth, and are very comparable to the slow growth kinetics of human CLC. The fact that mCLCs display constant and linear growth kinetics from the time of detection onward suggests that no additional mutations are required for CLC formation besides loss of E-cadherin and PTEN.

Interestingly, 17 out of 82 mCLCs showed a sudden transition from linear to exponential growth kinetics between 8 and 21 months after tumor detection ([Figure 4](#fig4){ref-type="fig"}D). These exponentially growing tumors displayed non-CLC phenotypes, including solid ILC and EMT-like tumors, which were also observed in a small fraction of the spontaneous tumors from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). The sudden and stochastic transition from linear to exponential growth kinetics suggests the acquisition of additional mutations in these tumors over time. Indeed, whole-exome sequencing of seven randomly selected exponentially growing tumors and 14 mCLCs revealed that all exponentially growing tumors harbored mutations in at least one cancer-related gene, while none of the mCLCs showed additional mutations ([Figure 4](#fig4){ref-type="fig"}E). Similarly, DNA copy-number variation (CNV) analysis showed that mCLCs displayed relatively stable genomic profiles, whereas exponentially growing tumors contained multiple DNA copy-number aberrations ([Figures 4](#fig4){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}B).

In summary, we successfully developed a mammary gland reconstitution model for CLC, highlighting a linear growth rate of these tumors and indicating that combined E-cadherin and PTEN loss is sufficient and, thus, causal for CLC development.

Metastatic Spectrum of mCLCs Mimics that of Human CLC {#sec2.5}
-----------------------------------------------------

Human CLC is characterized by its invasive and metastatic behavior. Similarly, mCLCs displayed tumor invasion, as detected by the examination of tumor sections, revealing irregular tumor edges with files of tumor cells invading surrounding tissues such as fat, muscle, and nerves ([Figures 5](#fig5){ref-type="fig"}A and 5B). In line with previous observations ([@bib5]), we observed a mixture of CK8 and cytokeratin-14 (CK14) double-positive tumor cells and CK14 single-positive tumor cells at the invasive front ([Figure S5](#mmc1){ref-type="supplementary-material"}A). We also investigated metastatic behavior for each tumor genotype. In *Wcre;Pten*^*F/+*^ and *Wcre;Pten*^*F/F*^ mice, no microscopic metastases could be detected in any organ, possibly due to the presence of intact adherens junctions ([Figure 5](#fig5){ref-type="fig"}C). In contrast, microscopic or macroscopic metastases were observed in 34% and 5% of tumor-bearing *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, respectively ([Figure 5](#fig5){ref-type="fig"}C). These metastases were detected at various distant sites that are also typical for human CLC, including lymph nodes, lungs, pleura, peritoneum, and abdominal viscera ([Figures 5](#fig5){ref-type="fig"}C and 5D). The distribution of the primary tumor phenotypes in mice that developed metastases was similar to the overall distribution, with the majority of primary tumors displaying an mCLC phenotype ([Figures 3](#fig3){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}B). A plausible explanation for the lower number of metastases in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice lies in the fact that these mice were sacrificed at a relatively young age (median, 210 days), as compared to *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ mice, which were sacrificed at a median age of 634 days ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Therefore, *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice might have been too young at the time of sacrifice to permit detection of (slow-growing) metastases. This notion is supported by the fact that the *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice with detectable metastases were the oldest of all mice analyzed ([Figure S5](#mmc1){ref-type="supplementary-material"}D). However, no metastatic lesions were observed in lungs from ten aged mice that had been reconstituted with mammary gland tissue from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice as described earlier ([Figure 4](#fig4){ref-type="fig"}B). Therefore, it cannot be excluded that the late onset of tumor formation in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ mice might favor the development of distinct ILCs with increased metastatic capacity.

Next, we used FACS analysis to search for single mCLC cells in the circulation or in common sites of human CLC metastasis, such as bone marrow or lungs. To facilitate the identification of single tumor cells, we used *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^*;mTmG* mice in which GFP expression marks *Wcre*-mediated loss of E-cadherin and PTEN ([@bib24]). IHC staining of mammary gland sections indeed confirmed the formation of GFP-positive mCLCs in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^*;mTmG* mice ([Figure S5](#mmc1){ref-type="supplementary-material"}E). FACS analysis of primary tumor tissue from five *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^*;mTmG* mice revealed 10%--15% GFP-positive cells, implying that the majority of cells in mCLC are non-tumor cells ([Figure 5](#fig5){ref-type="fig"}E). As expected, FACS analysis of blood samples revealed low numbers of circulating tumor cells (CTCs) in all *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^*;mTmG* mice analyzed, suggesting that tumor cells are able to shed from the primary tumor and intravasate into the blood circulation ([Figures 5](#fig5){ref-type="fig"}E and 5F). Furthermore, low numbers of GFP-positive cells were detected in bone marrow and lung tissue, indicating infiltration of disseminated tumor cells into these organs ([Figures 5](#fig5){ref-type="fig"}E and 5F). The low number of GFP-marked tumor cells might underestimate the actual number of disseminated tumor cells, as the presence of Tomato and GFP double-positive CTCs in the blood revealed incomplete switching of the homozygous *mTmG* reporter alleles. Nevertheless, these results show that mCLCs exhibit an invasive and metastatic behavior that strongly resembles that of human CLC.

Early Stromal Recruitment in CLC {#sec2.6}
--------------------------------

Histological and FACS analysis indicated mCLCs to contain a large proportion of non-tumor cells ([Figures 3](#fig3){ref-type="fig"}C and [5](#fig5){ref-type="fig"}E). Therefore, we performed a detailed histological characterization of the tumor microenvironment of mCLCs and compared it to that of human CLCs. Besides H&E staining, we included Masson's trichrome staining to visualize collagen fibers, a major component of the extracellular matrix, and IHC stainings to detect fibroblasts (PDGFRβ), T cells as a major component of the adaptive immune system (CD3), and macrophages as a major component of the innate immune system (F4/80 or CD68).

We analyzed both early lesions and more advanced tumors in 6-week-old and 25-week-old wild-type, *Wcre;Cdh1*^*F/F*^, *Wcre;Pten*^*F/F*^, and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, respectively ([Figure 6](#fig6){ref-type="fig"}A). In 6-week-old wild-type and *Wcre;Pten*^*F/F*^ mice ([Figures 6](#fig6){ref-type="fig"}A, [S6](#mmc1){ref-type="supplementary-material"}A, and S6B) and 25-week-old wild-type mice (data not shown), mammary ducts were surrounded by a thin layer of blue-colored collagen fibers and PDGFRβ-positive fibroblasts, containing few CD3-positive T cells and F4/80-positive macrophages. In contrast, mammary ducts of both *Wcre;Cdh1*^*F/F*^ and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice clearly showed an altered microenvironment. In *Wcre;Cdh1*^*F/F*^ mammary glands, a relatively normal epithelial layer was surrounded by an thickened layer of collagen fibers and fibroblasts, showing slightly increased numbers of macrophages, but no notable changes in T cell numbers ([Figure 6](#fig6){ref-type="fig"}A). Even more profound changes in the microenvironment of mammary ducts were observed in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. Early lesions of 6-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice showed a clear increase in collagen and numbers of fibroblasts and displayed increased numbers of infiltrating macrophages and T cells, especially at the periphery ([Figure 6](#fig6){ref-type="fig"}A). Similar phenotypes were observed in more advanced tumors of 25-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, indicating that stromal recruitment is a continuous process with preservation of the composition ([Figure 6](#fig6){ref-type="fig"}A).

To investigate whether the stromal composition of mCLC resembles that of human CLC, we analyzed breast tissue samples from five healthy individuals and tumor tissue from 12 CLC patients. Analysis of normal breast tissue yielded similar results as those from wild-type mice, showing little collagen and low numbers of fibroblasts, T cells, or macrophages surrounding mammary ducts ([Figure 6](#fig6){ref-type="fig"}B). Similar to mCLCs, human CLCs showed abundant collagen fibers and fibroblasts, infiltrating macrophages, and increased numbers of T cells that were mainly located at the tumor periphery ([Figure 6](#fig6){ref-type="fig"}B). In summary, both human CLCs and mCLCs arising in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice are heterotypic tumors characterized by a rich stromal compartment consisting mainly of collagen and fibroblasts.

Inhibition of PI3K Signaling Has Antitumor Activity in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ Mice {#sec2.7}
--------------------------------------------------------------------------------------------

As previously mentioned, the PI3K signaling pathway is frequently mutated in human ILC. In line with the role of PTEN as a negative regulator of PI3K signaling, CLCs from our *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mouse model showed activated PI3K signaling, as evidenced by elevated levels of p-AKT and p-S6 ([Figure 7](#fig7){ref-type="fig"}A). Given that improved treatments for human CLC are highly desirable, we asked whether the PI3K signaling pathway might be a potential therapeutic target for CLC. To this end, we performed a preclinical intervention study in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ female mice with the dual PI3K/mTOR (mammalian target of rapamycin) inhibitor BEZ235 ([@bib19]). Eight-week-old littermates were treated with BEZ235 or vehicle for a period of 28 days. Target inhibition of the PI3K signaling pathway by BEZ235 was confirmed by IHC and western blotting, showing decreased phosphorylation of both AKT and S6 in CLCs from mice treated with BEZ235 ([Figures 7](#fig7){ref-type="fig"}A and 7B). As expected, vehicle-treated *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ female mice showed, at the end of treatment, more and larger lesions than age-matched *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice did at the start of treatment (t = 0) ([Figures 7](#fig7){ref-type="fig"}C and 7D). Significantly fewer and smaller CLC lesions were observed in the mammary glands of BEZ235-treated littermates compared to t = 0 and vehicle-treated *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice, indicating that this PI3K/mTOR inhibitor strongly inhibited tumor formation in our mCLC model ([Figures 7](#fig7){ref-type="fig"}C and 7D). Together, these findings indicate that pharmacological inhibition of PI3K signaling may be a promising therapeutic strategy to target CLCs that harbor activating mutations in this pathway.

Discussion {#sec3}
==========

In this study, we show that concomitant inactivation of E-cadherin and PTEN leads to rapid formation of mouse mammary tumors that faithfully recapitulate the histopathology, molecular phenotype, ER status, growth kinetics, metastatic behavior, and tumor microenvironment of human CLC. Inactivating mutations of E-cadherin and PTEN co-occur in a substantial fraction (13%) of human ILCs ([@bib6]). In line with this, our data revealed potent synergism and causality between E-cadherin and PTEN inactivation in CLC formation. Previously, we reported that inactivation of E-cadherin and P53 in mammary epithelium results in the development of pleomorphic ILC, a relatively rare subtype of ILC ([@bib8], [@bib9]). In contrast, inactivation of PTEN alters the tumor outcome of E-cadherin-deficient cells toward CLC, which is the most common subtype of ILC ([@bib15]). Although E-cadherin inactivation alone is insufficient to induce tumor formation ([@bib3], [@bib8], [@bib9]), it appears to be required for ILC formation by dictating tumor outcome of P53- and PTEN-deficient mammary epithelial cells toward pleomorphic ILC and CLC, respectively. Thus, besides being recognized as a hallmark of ILC ([@bib32]), E-cadherin inactivation is also required for ILC formation.

In apparent contrast to its tumor-suppressor role, E-cadherin inactivation limits mammary epithelial cell survival in vivo as E-cadherin-deficient luminal epithelial cells were found to accumulate in the lumen of mammary ducts and undergo apoptosis, which is most likely due to reduced junctional integrity caused by E-cadherin loss ([@bib30]). Previously, E-cadherin inactivation in the mammary gland was found to limit the survival of alveolar cells during the onset of lactation ([@bib3]), supporting a role for E-cadherin in maintaining the survival of luminal mammary epithelial cells. E-cadherin-deficient mammary epithelium was also unable to expand in vitro and required concomitant inactivation of PTEN for outgrowth and invasion. PTEN inactivation also enabled the survival of E-cadherin-deficient mammary epithelial cells in vivo, permitting the formation of CLC. Importantly, as tumor onset in female *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice was extremely rapid, and no additional mutations were detected in the ensuing mCLCs, the combined inactivation of E-cadherin and PTEN appears to be sufficient and, thus, causal for CLC formation.

PTEN is an important negative regulator of the PI3K signaling pathway, which controls cell survival ([@bib7]). It is, therefore, likely that activation of PI3K signaling due to loss of PTEN promotes the survival of E-cadherin-deficient mammary epithelial cells and subsequent formation of CLC. Indeed, mCLCs from our *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mouse model showed activated PI3K signaling, as evidenced by expression of p-AKT and p-S6. Also, human ILCs were found to show frequent activation of PI3K signaling, as evidenced by increased AKT phosphorylation, reduced PTEN expression, and a high incidence of somatic mutations leading to PI3K pathway activation ([@bib6]). Together, these data suggest that PI3K pathway inhibitors might effectively target CLC. In line with this, mCLC formation in female *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice was significantly decreased by treatment with the dual PI3K/mTOR inhibitor BEZ235, indicating that the PI3K signaling pathway is an important Achilles' heel of CLC. At present, BEZ235 is under evaluation in phase I/II clinical trials ([@bib1]), and future studies are needed to investigate its efficacy in patients with CLC. However, it should be noted that antitumoral efficacy of PI3K pathway inhibitors might be reduced, in case CLCs acquire additional activating mutations in oncoproteins, such as KRAS, or loss-of-function mutations in tumor suppressors, such as PTPN11/SHP2 and p53, which we identified to alter tumor outcome and growth kinetics of mCLCs.

Other strategies to target CLC might involve targeting the tumor microenvironment, which can promote growth, metastasis, and therapy resistance of breast cancer ([@bib2], [@bib13], [@bib31]). Furthermore, the massive deposition of collagen in the tumor microenvironment of both mouse and human CLC suggests that collagen production is important for CLC development and progression. Collagen has been implicated in the induction of tumor cell invasion, as it was found to accumulate at invasive edges in breast tumors ([@bib10], [@bib28]) and to induce in vitro invasion of cultured breast tumor cells ([@bib25]). Similarly, tumor cells in mCLCs align with collagen as they invade the surrounding tissue. Both mouse and human CLC showed massive infiltration of fibroblasts, which are, in general, the main source of collagen deposition. Future studies will be required to investigate the importance of these cancer-associated fibroblasts (CAFs) for mCLC development and progression and whether targeting CAFs might provide a useful strategy for treatment of human CLC.

In conclusion, in this study we presented concomitant inactivation of E-cadherin and PTEN in mammary epithelium to drive the formation of mCLC, thus developing a pertinent mouse model for human CLC. This mouse model provides a powerful in vivo tool to develop novel therapeutic strategies for CLC patients, which may extend the relative limited treatment options that are currently available in the clinic.

Experimental Procedures {#sec4}
=======================

Generation of Mice {#sec4.1}
------------------

We intercrossed *Wcre;Cdh1*^*F/F*^ mice ([@bib9], [@bib8]) with *Pten*^*F/F*^ mice ([@bib20]) and *mTmG* reporter mice ([@bib24]). Mice were bred onto an FVB/N background and genotyped as described previously ([@bib8], [@bib20]); ([@bib24]). All animal experiments were approved by the Animal Ethical Committee and were conducted in compliance with the Netherlands Cancer Institute and Dutch Animal Welfare guidelines.

Isolation of Primary Mammary Epithelium for Organoid Generation {#sec4.2}
---------------------------------------------------------------

Purified primary mammary epithelial fragments were obtained from isolated mammary glands by mechanical disruption, collagenase/trypsin digestion, and differential centrifugation to generate organoids as previously described ([@bib12]). For additional details, see the [Supplemental Information](#app3){ref-type="sec"}.

Immunoblotting, IF, and Histopathology {#sec4.3}
--------------------------------------

Immunoblotting, IF, and histopathological analysis was performed as described in the [Supplemental Information](#app3){ref-type="sec"}.

Mammary Gland Reconstitution {#sec4.4}
----------------------------

Mammary gland reconstitutions were performed based on previously described mouse mammary epithelial cell transplantation ([@bib11]). In brief, the fourth mammary glands of 18- to 21-day-old wild-type or *mTmG* mice on FVB/N background were cleared by surgical removal of the epithelium-containing part, including the lymph node, and were engrafted with small fragments (1-2 mm in diameter) of mammary gland tissue from 5- to 6-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. Transplanted mice were checked biweekly for the development of tumors.

Genomic Analysis {#sec4.5}
----------------

RNA sequencing, whole-exome sequencing, and CNV analysis was performed as described in the [Supplemental Information](#app3){ref-type="sec"}.

Flow Cytometry {#sec4.6}
--------------

Blood samples were collected in tubes containing heparin. Tumors and lungs were mechanically chopped using a McIlwain tissue chopper (Mickle Laboratory Engineering), followed by digestion for 1 hr at 37°C in 3 mg/ml collagenase type A (Roche) and 25 μg/ml DNase (Sigma-Aldrich) in serum-free DMEM medium. Enzyme activity was neutralized by the addition of cold DMEM/10% fetal bovine serum (FBS), and suspensions were dispersed through a 70-μm cell strainer. Bone marrow was isolated through the flushing of two femurs using PBS. All single-cell suspensions were treated with erythrocyte lysis buffer (0.15 M NH~4~Cl, 10 mM KHCO~3~, 0.5 M EDTA) and collected in PBS + 1% BSA. DAPI (1:20) was added to exclude dead cells. GFP-positive cells were analyzed using a Beckman Coulter CyAn ADP flow cytometer and FlowJo software.

BEZ235 Intervention Study {#sec4.7}
-------------------------

Eight-week-old littermates were orally dosed on a daily basis with 30 mg/kg BEZ235 dissolved in 10% N-methyl-2-pyrrolidone/90% PEG 400 (polyethylene glycol 400) (Sigma-Aldrich) or vehicle for a period of 28 days. Two hours after the last dosing, mice were sacrificed, and mammary glands were harvested for further analysis. Antitumor activity was assessed by calculating the ratio between the sum of all CLC regions and the total mammary gland area using ImageJ.

Statistics {#sec4.8}
----------

The following statistics were used for the indicated figures: for [Figures 1](#fig1){ref-type="fig"}C, 1E, [2](#fig2){ref-type="fig"}D, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D, an unpaired t test was used; for [Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A, we used a log-rank Mantel-Cox test; for [Figure 3](#fig3){ref-type="fig"}D, a Mann-Whitney test was used; for [Figure S3](#mmc1){ref-type="supplementary-material"}C, differential expression was assessed using limma ([@bib29]); and a one-tailed Mann-Whitney U test was used for [Figure 4](#fig4){ref-type="fig"}E. For [Figure 7](#fig7){ref-type="fig"}D, a paired t test was performed on these ratios between BEZ235- and vehicle-treated littermates.
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![Inactivation of E-Cadherin and PTEN Alters Mammary Epithelial Morphology and Growth In Vitro\
(A) Western blot analyses of E-cadherin, PTEN, and p-AKT(Ser473)/AKT protein expression of untransduced and AdCre-transduced *Cdh1*^*F/F*^, *Pten*^*F/F*^, and *Cdh1*^*F/F*^*;Pten*^*F/F*^ mammary organoids.\
(B) Representative bright-field images of untransduced and AdCre-transduced *Cdh1*^*F/F*^, *Pten*^*F/F*^, and *Cdh1*^*F/F*^*;Pten*^*F/F*^ mammary organoids at day 21 of organoid culture. The dashed circle depicts the surface size of AdCre-transduced *Cdh1*^*F/F*^ organoids. Scale bar, 50 μm.\
(C) Average measurements of surface size (n = 10 per genotype) of untransduced and AdCre-transduced *Cdh1*^*F/F*^, *Pten*^*F/F*^, and *Cdh1*^*F/F*^*;Pten*^*F/F*^ organoids at days 7, 14, and 21 of organoid culture.\
(D) Expression of Ki67 and CC3 measured by whole-mount immunostaining of AdCre-transduced *Cdh1*^*F/F*^, *Pten*^*F/F*^, and *Cdh1*^*F/F*^*;Pten*^*F/F*^ organoids. Scale bars, 50 μm.\
(E) Quantification of the fraction of Ki67- and CC3-positive cells over the total cell number (determined by Hoechst) in AdCre-transduced *Cdh1*^*F/F*^*, Pten*^*F/F*^, and *Cdh1*^*F/F*^*;Pten*^*F/F*^ (n = 10 per genotype).\
(F) Representative bright-field images of a *Cdh1*^*F/F*^*;Pten*^*F/F*^ organoid displaying invasive protrusions of single rows of cells (arrows) 1 day after medium change. Scale bars, 25 μm.](gr1){#fig1}

![Inactivation of E-Cadherin and PTEN in Mammary Epithelium In Vivo Induces Rapid Formation of Neoplastic Lesions\
(A) H&E staining and IHC of CK8 in mammary glands from 6-week-old wild-type, *Wcre;Cdh1*^*F/F*^*, Wcre;Pten*^*F/F*^, and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. Scale bars, 150 μm.\
(B) IF analysis of CK8, E-cadherin, and PTEN in mammary glands from 6-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. Scale bar, 20 μm. Zooms of the asterisk-marked area reveal CK8-positive neoplastic cells that are negative for of E-cadherin and PTEN (indicated by arrows), flanked by PTEN-positive stromal cells.\
(C) IF analysis of CK8 (green) and CC3 (red) in mammary glands from 6-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. Arrows mark CC3-positive apoptotic cells in the mammary duct. Scale bar, 20 μm.\
(D) Average numbers of CC3-positive shedded cells per 500-μm^2^ area in mammary gland sections from *Wcre;Cdh1*^*F/F*^*, Wcre;Pten*^*F/F*^*and Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice.](gr2){#fig2}

![Somatic Inactivation of E-Cadherin and PTEN Induces Mammary Tumors that Closely Resemble Human CLC\
(A) Mammary tumor-free survival plot of *Wcre;Pten*^*F/+*^ (n = 26), *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ (n = 39), *Wcre;Pten*^*F/F*^ (n = 23), and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ (n = 60) mice. Latency is shown in days of age. n.s., not significant.\
(B) Pie charts showing the distribution of mammary tumor phenotypes in *Wcre;Pten*^*F/+*^ (n = 7), *Wcre;Cdh1*^*F/F*^*; Pten*^*F/+*^ (n = 23), *Wcre;Pten*^*F/F*^ (n = 28), and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ (n = 238) mice.\
(C) Representative H&E staining and IHC of CK8, Vimentin, E-cadherin, PTEN, and ER in mammary tumors from 12-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice. Scale bars, 25 μm. The zoom of the asterisk-marked area reveals PTEN-negative tumor cells flanked by PTEN-positive stromal cells.\
(D) Quantification of ER-positive tumor cells detected by IHC of ER in *Brca1*^*Δ/Δ*^*;Trp53*^*Δ/Δ*^ (n = 10) and *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ (n = 14) mammary tumors.\
(E) Unsupervised hierarchical clustering of 956 human breast cancer samples, 22 *Brca1*^*Δ/Δ*^*;Trp53*^*Δ/Δ*^ mammary tumor samples, and 20 *Cdh1*^*Δ/Δ*^*;Pten*^*Δ/Δ*^ mCLC samples. Sidebars indicate tumor subtype according to PAM50 for the human breast tumors, genotypes for the mouse mammary tumors, and *Cdh1* mutation status for all tumors.](gr3){#fig3}

![Mammary Gland Transplantation Reveals Linear Growth Kinetics of mCLCs\
(A) Mammary-tumor-free survival in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice and wild-type mice transplanted with small precancerous mammary gland fragments from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice.\
(B) Average size of tumors in mice transplanted with precancerous *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mammary gland fragments (n = 82).\
(C) Pie chart showing distribution of tumor phenotypes from mice transplanted with precancerous *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mammary gland fragments (n = 58).\
(D) A fraction (n = 17) of mice transplanted with precancerous *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mammary gland fragments showed a sudden transition from linear to exponential growth 250--450 days after tumor onset.\
(E) Overview of oncogenic mutations identified in exponentially growing solid ILCs and EMT tumors.\
(F) Number of genomic aberrations in linear-growing mCLCs (n = 14) or exponential-growing solid ILCs and EMT tumors (n = 7).](gr4){#fig4}

![Metastatic Spectrum of mCLCs\
(A and B) Representative H&E stainings revealing tumor cell invasion into surrounding muscular tissue (A) and nerve tissue (B) in mammary glands from 12-week-old *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice (scale bars, 100 μm).\
(C) Incidence of distant metastases in *Wcre;Pten*^*F/+*^ (n = 15), *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ (n = 32), *Wcre;Pten*^*F/F*^ (n = 26), and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ (n = 62) mice. Colors depict different metastatic sites in metastasis-bearing *Wcre;Cdh1*^*F/F*^*;Pten*^*F/+*^ (n = 11) and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ (n = 3) mice.\
(D) Representative H&E stainings of tumor infiltration (marked by asterisks) in lymph node, lung, pleura, peritoneum, and spleen. Scale bars, 200 μm.\
(E) Representative FACS plots of GFP-sorted cells obtained from mammary tumors, blood, lungs, and bone marrow of tumor-bearing *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^;*mTmG* mice, revealing dissemination of GFP-marked tumor cells to distant organs.\
(F) Fractions of *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^;*mTmG* mice (n = 5) harboring GFP-marked tumor cells in indicated organs.](gr5){#fig5}

![Early Stromal Recruitment in Mouse and Human CLC\
(A and B) In (A), H&E and Masson's trichrome staining (revealing collagen) and IHC of PDGFRβ (fibroblasts), CD3 (T cells), and F4/80 (macrophages) in tumor-free mammary glands and mCLCs from wild-type, *Wcre;Cdh1*^*F/F*^, *Wcre;Pten*^*F/F*^, and *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice of indicated age were used to examine stromal compositions in each indicated genotype, which were subsequently compared to (B) the microenvironment of healthy human mammary glands and the tumor microenvironment of human CLCs.](gr6){#fig6}

![Inhibition of PI3K Signaling Has Antitumor Activity in *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ Mice\
(A) Representative IHC of p-AKT and p-S6, reflecting PI3K signaling activity in mCLCs from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice treated with either vehicle or BEZ235.\
(B) Western blot analysis of p-AKT/AKT and p-S6/S6 expression, reflecting PI3K signaling activity in mCLCs from vehicle-treated and BEZ235-treated *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice.\
(C) H&E staining of mammary glands from *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice treated with vehicle or BEZ235. Lesions are indicated by arrows.\
(D) Quantification of lesion formation by measuring total lesion area over total mammary gland tissue area for vehicle-treated (n = 6) and BEZ235-treated (n = 6) *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ littermates, compared to age-matched *Wcre;Cdh1*^*F/F*^*;Pten*^*F/F*^ mice (n = 9) at start of treatment (t = 0).](gr7){#fig7}
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